Compare AGCO Corporation (AGCO) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGCO Corporation vs BIO-TECHNE Corp — how do they compare? AGCO Corporation trades at $101.37 (market cap $7.06B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and AGCO Corporation pays the higher dividend (1.19%). Which is the better fit depends on your goals.
| AGCO | TECH | |
|---|---|---|
Market Cap | $7.06B | $11.24B |
Sector | Industrials | Health |
52-Week High | $140.49 | $72.29 |
52-Week Low | $100.14 | $43.31 |
Enterprise Value | $9.33B | $11.32B |
Dividend Yield | 1.19% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGCO trades at $102.83, up 1.18% on the day, but faces bearish technical signals with the stock trading near key support at $102. The agricultural equipment manufacturer reported mixed Q2 2026 results, missing earnings estimates but maintaining a solid balance sheet with $612 million in cash. Recent leadership changes and multiple securities investigations create uncertainty, though the company's valuation remains attractive with a P/E of 14.22 and P/S of 0.73.
While AGCO's fundamentals show resilience with positive cash flow and reasonable valuation, near-term headwinds from weaker industry conditions and legal scrutiny present significant risks. The 37.9% analyst buy rating and $124.63 price target suggest potential upside, but investors should weigh the bearish technical outlook against the company's long-term positioning in precision agriculture.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGCO Corporation
Agco is a global manufacturer of agricultural equipment. The company has five principal brands: Fendt, Massey Ferguson, Challenger, Valtra, and GSI. Unlike its competitors, Agco's product line extends beyond self-propelled equipment and implements by offering grain handling systems and livestock management solutions. Its products are available through a global dealer network, which includes over 3,200 dealer and distribution locations. Additionally, Agco offers both retail and wholesale financing to customers through its joint venture with Rabobank, a European food and agriculture focused bank.
Read more on AGCO →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
